Publication | Open Access

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

VaccinationCross-protectionVaccine DevelopmentVaccine TargetImmunologyLong-lasting ImmunityVaccine EfficacyInfluenza VaccineImmunotherapyMedicineViral ImmunityPlacebo-controlled PhaseInfluenza Vaccines